Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Aluminum – calcium or magnesium element – or compound containing
Patent
1992-05-06
1993-07-20
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Aluminum, calcium or magnesium element, or compound containing
424690, 424692, 424717, 514 63, 514365, 514370, 514400, 514461, 514819, 514820, A61K 3310, A61K 3308, A61K 3300, A61K 31695, A61K 31425, A61K 31415, A61K 3134
Patent
active
052291375
ABSTRACT:
Pharmaceutical medications and methods are disclosed for providing instant and sustained relief from pain or symptoms associated with episodic heartburn in humans. The medications consist essentially of antacids and histamine H.sub.2 -receptor antagonists, and may be administered on an as-needed basis in liquid or solid dosage forms. Typical antacids which may be used in combination with the histamine H.sub.2 -receptor antagonist are conventional antacids which are well known and widely used in the treatment of excess acid related gastrointestinal dysfunctions. Exemplary of typical antacids include, sodium bicarbonate, calcium carbonate, magnesium hydroxide and aluminum hydroxide, as well as commercially available high potency, flavored antacids. Histamine H.sub.2 -receptor antagonists which may be used in combination include those conventionally used in the treatment of peptic ulcers, such as, for example, cimetidine, ranitidine, famotidine and nizatidine. In carrying out the methods, an antacid and histamine H.sub.2 -receptor antagonist may be administered together as a single unitary dose in the form of a liquid or solid, or administered together, but separately as either liquids or solids or a combination thereof. The oral medications when formulated as a single unitary dose may include other additives, such as, for example, antiflatulents, flavorings, sweeteners and the like.
REFERENCES:
patent: 4127650 (1978-11-01), Buehler
patent: 4316888 (1982-02-01), Nelson
patent: 4676984 (1987-06-01), Wu et al.
patent: 4684632 (1987-08-01), Schultz
patent: 4689229 (1987-08-01), Banik
patent: 4704278 (1987-11-01), Wu et al.
patent: 4705683 (1987-11-01), Dettmar
patent: 4846836 (1989-07-01), Reich
patent: 4857324 (1989-08-01), Mir et al.
patent: 4861592 (1989-08-01), Gottwald et al.
patent: 4918063 (1990-04-01), Lichtenberger
patent: 4950656 (1990-08-01), Lichtenberger
Avery's Drug Treatment, 3rd edition (1987) pp. 742-743.
Steinberg, W. M. et al.: N Engl J Med, 307(7):400-404 (Aug. 12, 1982).
Mihaly, G. W. et al.: Br Med J, 285:998-999 (Oct. 9, 1982).
Harvey, Stewart C., "Chapter 42: Gastric Antacids, Miscellaneous Drugs for the Treatment of Peptic Ulcers, Digestions, and Bileacids" Goodman & Gilman's The Pharmacological Basis of Therapeutics, 7th Ed., McMillan (1985).
Douglas, W., "Chaper 26: Histamine and 5-Hydroxy-Tryptamine (Serotonin) and Their Antagonists," Goodman & Gilman's The Pharmacological Basis of Therapeutics, 7th Ed., McMillan Publishing (1985).
O'Laughlin et al.: "Healing of Aspirin-Associated Peptic Ulcer Disease Despite Continued Colicilate Injection", Archives of Internal Medicine, 141:781-783 (1981).
Weserstein, M. et al.: "In Vivo Evaluation of the Effect of Antacids and H.sub.2 Blockers and Intragastric pH in the Gastric and Duodeanl Ulser," Acta Gastroenterol. Latinoam, 15(4):243-256 (1985).
Histamine H.sub.2 -Receptor Antagonists Systemic, USP DI Review Page, 1-24 (Jun. 17, 1992).
Frislid, K. et al.: Br Med J, 286:1358 (1983).
S. van Avermaet et al.: Gastroenterology, 102 (4) Part II, A184 Abstracts (1992).
Drug Evaluation Monographs, Micromedex, Inc. 76 Exp. (May 31, 1993).
Drug Evaluation Monographs, Micromedex, Inc., 76 Exp. (May 31, 1993).
Drug Consults, Micromedex, Inc., 76 Exp. (May 31, 1993).
Drug Interaction Facts, Facts and Comparisons, 338 (Apr., 1991).
Drug Interaction Facts, Facts and Comparisons, 187 (Jul., 1991).
Lin, H. F.: Clin. Pharmacokinet., 20(3):218-236 (1991).
Desager, J. P. et al.: J. International Medical Research, 17:62-67 (1989).
Drug Interaction Facts, Facts and Comparisons, 612 (Jul., 1990).
Stockley, I. H.: Drug Ineractions, A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management, 2nd Ed., Blackwell Scientific Publicaitons 614-615 (1991).
Shelly, D. W. et al.: Drug Intell. Clin. Pharm., 20:792-795 (Oct., 1986).
Albin, H. et al.: Eur. J. Clin. Pharmacol., 32:97-99 (1987).
D'Arcy, P. F. et al.: Drug Intell. Clin. Pharm., 21:607-617 (1987).
Donn, K. H. et al.: Pharmacotherapy, 4:89-92 (1984).
Hansten, P. D. et al.: Drugs Interactions Newsletter, 5(3):11-14 (Mar., 1985).
Gannoulis, N. et al.: Gastroenterology, 90:A1393 (May, 1986).
Albin, H. et al.: Eur. J. Clin. Pharmacol., 26:271-273 (1984).
Russell, W. L. et al.: Digestive Diseases and Sciences, 29(5):385-389 (May, 1984).
Mahachai, V. et al.: Clinical Therapeutics, 6(6):808-823 (1984).
Steinberg, W. M. et al.: Gastroenterology, 78:A1269 (May, 1980).
Gugler, R. et al.: Eur. J. Clin. Pharmacol., 20:225-228 (1981).
Gugler, R. et al.: Clin. Pharmacol. Ther., 29(6):744-748 (Jun., 1981).
Bodemar, G. et al.: Br. Soc. Gastroenterology, 19:A990 (1979).
Bodemar, G. et al.: Lancet (Letter), 444-445 (Feb. 24, 1979).
Ganjian, F. et al.: J. Pharm. Sci., 69(3):352-353 (Mar., 1980).
Burland, W. L. et al.: Lancet, (Letter) 965 (Oct. 30, 1976).
Longstreth, G. F. et al.: Gastroenterology, 72(1):9-13 (1977).
Clayman, C. B.: JAMA, 238(12):1289-1290 (Sep. 19, 1977).
Lin, J. H. et al.: Br. J. Clin. Pharmac., 24:551-553 (1987).
Gallaghan, J. T. et al.: Scanned J. Gastroenterol., 22(Suppl 136):9-17 (1987).
Barzaghi, N. et al.: Eur. J. Clin. Pharmacol., 37:409-410 (1989).
Brigham and Women's Hospital, Inc.
Henley III Raymond J.
Waddell Frederick E.
LandOfFree
Methods and pharmaceutical compositions for treating episodic he does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and pharmaceutical compositions for treating episodic he, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and pharmaceutical compositions for treating episodic he will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1758927